ArticleViruses2019
Inhibition of
Article in Viruses, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 40 citations in OpenAlex.
- Endolysin-based biocontrol strategies againstFood science and biotechnology · 2025Review
- From discovery to potential application: engineering a novel M23 peptidase to combat Listeria monocytogenes.Scientific reports · 2025Article
- Phage-Based Control ofViruses · 2025Review
- Degradation of Preformed Gram-Positive and Gram-Negative Bacterial Biofilms Using Disintegrated and Intact Phages.PHAGE (New Rochelle, N.Y.) · 2025Article
- Antibacterial activity of endolysin LysP70 fromFrontiers in microbiology · 2025Article
- Synergistic Enzybiotic Effect of a Bacteriophage Endolysin and an Engineered Glucose Oxidase AgainstBiomolecules · 2024Article
- Review
- Review
- A comprehensive review of the applications of bacteriophage-derived endolysins for foodborne bacterial pathogens and food safety: recent advances, challenges, and future perspective.Frontiers in microbiology · 2023Review
- The Mechanism of Bacterial Resistance and Potential Bacteriostatic Strategies.Antibiotics (Basel, Switzerland) · 2022Review
- Phage Products for Fighting Antimicrobial Resistance.Microorganisms · 2022Review
- Inhibition ofFoods (Basel, Switzerland) · 2022Article
- Treating Bacterial Infections with Bacteriophage-Based Enzybiotics: In Vitro, In Vivo and Clinical Application.Antibiotics (Basel, Switzerland) · 2021Review
- Endolysin, a Promising Solution against Antimicrobial Resistance.Antibiotics (Basel, Switzerland) · 2021Review
- An Enzybiotic Regimen for the Treatment of Methicillin-ResistantAntibiotics (Basel, Switzerland) · 2021Article
- Phage φAB6-Borne Depolymerase CombatsAntibiotics (Basel, Switzerland) · 2021Article
- Comparison ofViruses · 2021Article
- Phage Endolysin LysP108 Showed Promising Antibacterial Potential Against Methicillin-resistantFrontiers in cellular and infection microbiology · 2021Article
- Characterization of a Lytic Bacteriophage vB_EfaS_PHB08 Harboring Endolysin Lys08 AgainstMicroorganisms · 2020Article
- Polyvalent Phage CoNShP-3 as a Natural Antimicrobial Agent Showing Lytic and Antibiofilm Activities against Antibiotic-Resistant Coagulase-Negative Staphylococci Strains.Foods (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.